Good Times
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Good Times

› Forums › General Melanoma Community › Good Times

  • Post
    • July 28, 2016 at 3:35 pm
    _Paul_
    Participant

    Hi All,

    I took a break from the board for a few months to enjoy my NEDness. It was great. But now I am back because one of my the presumed dead tumors decided otherwise. My onc at the SCCA is talking to me about this trial: https://clinicaltrials.gov/show/NCT02410512. It combines ANTI-PD-L1 with MOXR0916, a humanized agonist anti-OX40 monoclonal antibody. I am trying to find out about the trial, like dosing schedule, toxicities, and the like. Is there anyone here on the trial that can share your experience?

    Thanks – Paul

Viewing 11 reply threads
  • Replies
      • July 28, 2016 at 6:35 pm
      Mat
      Participant

      Paul, glad to hear that you're doing well.  When I met with Weber last fall, OX-40 seemed to be the big new thing.  Combining with PDL1 sounds even better.  I assume that your keeping ipi-nivo in your back pocket?

        • July 28, 2016 at 7:25 pm
        _Paul_
        Participant

        Hey Mat, yep, still kickin'. I have a bunch of plan B's at the moment: resection (although its not in a great spot, SRS, TIL (my T-cells are on ice) and the combo. I have had a good number of side effects from both IPI and Pembro, so the combo is lower on the list, but I am glad I have it as an option.

        How have you been?

        • July 28, 2016 at 7:25 pm
        _Paul_
        Participant

        Hey Mat, yep, still kickin'. I have a bunch of plan B's at the moment: resection (although its not in a great spot, SRS, TIL (my T-cells are on ice) and the combo. I have had a good number of side effects from both IPI and Pembro, so the combo is lower on the list, but I am glad I have it as an option.

        How have you been?

        • July 28, 2016 at 7:25 pm
        _Paul_
        Participant

        Hey Mat, yep, still kickin'. I have a bunch of plan B's at the moment: resection (although its not in a great spot, SRS, TIL (my T-cells are on ice) and the combo. I have had a good number of side effects from both IPI and Pembro, so the combo is lower on the list, but I am glad I have it as an option.

        How have you been?

      • July 28, 2016 at 6:35 pm
      Mat
      Participant

      Paul, glad to hear that you're doing well.  When I met with Weber last fall, OX-40 seemed to be the big new thing.  Combining with PDL1 sounds even better.  I assume that your keeping ipi-nivo in your back pocket?

      • July 28, 2016 at 6:35 pm
      Mat
      Participant

      Paul, glad to hear that you're doing well.  When I met with Weber last fall, OX-40 seemed to be the big new thing.  Combining with PDL1 sounds even better.  I assume that your keeping ipi-nivo in your back pocket?

      • July 28, 2016 at 8:42 pm
      ed williams
      Participant

      Hi Paul, what have the early trials with moxro916 showed as far as side effects? These new go signal (activating) agents seems really interesting, I would be curious about side effect profile. Is the trial set up to get it as monotherapy as an option or is it only going to be offered as a combination with the  pd-L1 inhibitor(Atezolizumab). Best wishes!!!Ed

        • July 29, 2016 at 1:49 pm
        _Paul_
        Participant

        Hi Ed,

        The trial offers both of them as a combo, with or without Avastin. The side effect profile of OX-40 appears to be less than PD-1 or PD-L1. This is from the consent form:

        MOXR0916 is in an early phase of clinical development. As of 12 November 2015, safety data is available for 102 patients treated with MOXR0916 alone (the GO29313 study). Dose levels for these patients ranged from 0.2 mg to 1200 mg. Eighty-seven patients have had at least one side effect while taking MOXR0916.
        Most of these side effects were mild or moderate and included the following:
         Feeling tired (fatigue)
         Rash, hives or itchy skin
         Diarrhea
         Infusion-related reactions (allergic reaction)
         Nausea
        Severe side effects included:
         Inflammation of the liver (autoimmune hepatitis)
         Shortness of breath (dyspnea)
         Feeling tired (fatigue)
         Increased blood pressure (hypertension)
         Decrease in specific white blood cells (lymphopenia)
        Each of these side effects happened in one patient. There have been no deaths related to MOXR0916.
         
        – Paul
        • July 29, 2016 at 1:49 pm
        _Paul_
        Participant

        Hi Ed,

        The trial offers both of them as a combo, with or without Avastin. The side effect profile of OX-40 appears to be less than PD-1 or PD-L1. This is from the consent form:

        MOXR0916 is in an early phase of clinical development. As of 12 November 2015, safety data is available for 102 patients treated with MOXR0916 alone (the GO29313 study). Dose levels for these patients ranged from 0.2 mg to 1200 mg. Eighty-seven patients have had at least one side effect while taking MOXR0916.
        Most of these side effects were mild or moderate and included the following:
         Feeling tired (fatigue)
         Rash, hives or itchy skin
         Diarrhea
         Infusion-related reactions (allergic reaction)
         Nausea
        Severe side effects included:
         Inflammation of the liver (autoimmune hepatitis)
         Shortness of breath (dyspnea)
         Feeling tired (fatigue)
         Increased blood pressure (hypertension)
         Decrease in specific white blood cells (lymphopenia)
        Each of these side effects happened in one patient. There have been no deaths related to MOXR0916.
         
        – Paul
        • July 29, 2016 at 1:49 pm
        _Paul_
        Participant

        Hi Ed,

        The trial offers both of them as a combo, with or without Avastin. The side effect profile of OX-40 appears to be less than PD-1 or PD-L1. This is from the consent form:

        MOXR0916 is in an early phase of clinical development. As of 12 November 2015, safety data is available for 102 patients treated with MOXR0916 alone (the GO29313 study). Dose levels for these patients ranged from 0.2 mg to 1200 mg. Eighty-seven patients have had at least one side effect while taking MOXR0916.
        Most of these side effects were mild or moderate and included the following:
         Feeling tired (fatigue)
         Rash, hives or itchy skin
         Diarrhea
         Infusion-related reactions (allergic reaction)
         Nausea
        Severe side effects included:
         Inflammation of the liver (autoimmune hepatitis)
         Shortness of breath (dyspnea)
         Feeling tired (fatigue)
         Increased blood pressure (hypertension)
         Decrease in specific white blood cells (lymphopenia)
        Each of these side effects happened in one patient. There have been no deaths related to MOXR0916.
         
        – Paul
      • July 28, 2016 at 8:42 pm
      ed williams
      Participant

      Hi Paul, what have the early trials with moxro916 showed as far as side effects? These new go signal (activating) agents seems really interesting, I would be curious about side effect profile. Is the trial set up to get it as monotherapy as an option or is it only going to be offered as a combination with the  pd-L1 inhibitor(Atezolizumab). Best wishes!!!Ed

      • July 28, 2016 at 8:42 pm
      ed williams
      Participant

      Hi Paul, what have the early trials with moxro916 showed as far as side effects? These new go signal (activating) agents seems really interesting, I would be curious about side effect profile. Is the trial set up to get it as monotherapy as an option or is it only going to be offered as a combination with the  pd-L1 inhibitor(Atezolizumab). Best wishes!!!Ed

      • July 29, 2016 at 1:04 am
      Bubbles
      Participant

      Sorry to hear that, Paul. Here's what I have on OX40: http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2016/05/asco-2016-other-therapies-after-failing.html

      And there's this by Weber that may have some options you can talk with your doc about:  http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2016/03/immunology-updatewebinar-for-melanoma.html

      Hang in there! Celeste

        • July 29, 2016 at 2:31 pm
        _Paul_
        Participant

        Thanks Celeste! As always, you are a treasure trove of information.

        – Paul

        • July 29, 2016 at 2:31 pm
        _Paul_
        Participant

        Thanks Celeste! As always, you are a treasure trove of information.

        – Paul

        • July 29, 2016 at 2:31 pm
        _Paul_
        Participant

        Thanks Celeste! As always, you are a treasure trove of information.

        – Paul

      • July 29, 2016 at 1:04 am
      Bubbles
      Participant

      Sorry to hear that, Paul. Here's what I have on OX40: http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2016/05/asco-2016-other-therapies-after-failing.html

      And there's this by Weber that may have some options you can talk with your doc about:  http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2016/03/immunology-updatewebinar-for-melanoma.html

      Hang in there! Celeste

      • July 29, 2016 at 1:04 am
      Bubbles
      Participant

      Sorry to hear that, Paul. Here's what I have on OX40: http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2016/05/asco-2016-other-therapies-after-failing.html

      And there's this by Weber that may have some options you can talk with your doc about:  http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2016/03/immunology-updatewebinar-for-melanoma.html

      Hang in there! Celeste

      • August 1, 2016 at 6:14 am
      adriana cooper
      Participant

      Paul, Sorry to hear of the setback. Hope it's only minor and it gets it's a** kicked. Adriana still clear and off meds since last scans and when we last met at the conference although she has been having some unexplained back pain. Good luck and keep in touch. Rob and Adriana.

        • August 4, 2016 at 3:02 am
        _Paul_
        Participant

        That's awesome new Rob! Nice to hear from you as well. When was the last she she had a scan?

        • August 4, 2016 at 3:02 am
        _Paul_
        Participant

        That's awesome new Rob! Nice to hear from you as well. When was the last she she had a scan?

        • August 4, 2016 at 3:02 am
        _Paul_
        Participant

        That's awesome new Rob! Nice to hear from you as well. When was the last she she had a scan?

      • August 1, 2016 at 6:14 am
      adriana cooper
      Participant

      Paul, Sorry to hear of the setback. Hope it's only minor and it gets it's a** kicked. Adriana still clear and off meds since last scans and when we last met at the conference although she has been having some unexplained back pain. Good luck and keep in touch. Rob and Adriana.

      • August 1, 2016 at 6:14 am
      adriana cooper
      Participant

      Paul, Sorry to hear of the setback. Hope it's only minor and it gets it's a** kicked. Adriana still clear and off meds since last scans and when we last met at the conference although she has been having some unexplained back pain. Good luck and keep in touch. Rob and Adriana.

Viewing 11 reply threads
  • You must be logged in to reply to this topic.
About the MRF Patient Forum

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

Popular Topics